# Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

> **NCT03187691** · PHASE2 · WITHDRAWN · sponsor: **Matinas BioPharma Nanotechnologies, Inc.**

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Oral Encochleated Amphotericin B (CAMB)

## Key facts

- **NCT ID:** NCT03187691
- **Lead sponsor:** Matinas BioPharma Nanotechnologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-08
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Protocol redundancy
- **Last updated:** 2019-03-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03187691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03187691, "Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03187691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*